The size of the single-cell analysis market in the Asia Pacific is estimated to be worth USD 1.01 billion by 2028 from USD 0.45 billion in 2023. This market is forecasted to grow at a CAGR of 17.92% from 2023 to 2028.
The growing focus on personalized medicine, increased R&D in the pharmaceutical and biotechnology industries for complicated diseases, rise in stem cell research, and the increasing frequency of pandemics drive the Asia Pacific single-cell analysis market. As firms focus on creating targeted medicines, single-cell analysis kits have become increasingly important for assessing the genetic profile of clinical trial participants. The market's rise may be attributed to increased investments and government money allocated to medical diagnostics research and development (R & R&D), the availability of technically improved products, and the increased usage of single-cell analysis equipment. In addition, the use of high throughput technologies in assays has expanded due to the advent of single-cell amplification and manipulation techniques, leading to higher revenue. Furthermore, the rapid development of microfluidic equipment has considerably expanded the use of single-cell genomic analysis in biomedical research.
During the forecast period, the Asia Pacific market is expected to develop at the fastest rate. Some of the other main factors driving demand for single-cell analysis consumables and instruments during this regional firestorm include the presence of a large patient population (especially in China and India) and growth in the outsourcing of drug discovery services to Asian CROs. In addition, factors including the burgeoning medical tourism business, fast-improving healthcare infrastructure, and rising disposable income have fueled demand for modern diagnostic technologies in Asia Pacific's emerging nations in recent years. The region's market is predicted to be driven by concentrated efforts, with the greatest CAGR during the forecast period. The immunological responses of COVID-19 patients can be assessed using a high-throughput single-cell analytic technique. Single-cell RNA sequencing was used on 284 samples of COVID-19-infected patients in 2022, allowing for the study and association of various peripheral immune subtype alterations with clinical parameters such as age, sex, and severity.
However, the high cost of single-cell analysis products is projected to hinder market expansion during the forecast period.
This research report on the APAC single-cell analysis market has been segmented and sub-segmented into the following categories:
Geographically, in 2022, Japan dominated the Asia Pacific single-cell analysis market, and this trend is expected to continue in the following years. The single-cell analysis market in Japan is developing due to rising life science research activities, rising demand for enhanced treatment procedures, and a growing focus on medicine.
China was a close second to Japan in terms of market share in 2022. However, Japan's share of the APAC single-cell analysis market is predicted to grow over the next five years, as its CAGR is expected to be greater than China's. The rising number of research publications reflects the market's growing R&D investment. These investments indicate a high growth potential for this market, as R&D activities are the foundation of innovation. Furthermore, researchers are evaluating regional variability in gene expression profiles at a single cellular level, which is expected to increase demand for consumables and devices for the analysis. Because of many government programs to improve healthcare infrastructure, the availability of skilled professionals to work with new analytical tools, and rising healthcare spending, the Asia-Pacific region is leading the way.
KEY MARKET PLAYERS:
Companies playing a prominent role in the APAC single-cell analysis market profiled in this report are Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, General ElectricCompany, Thermo Fisher Scientific, Miltenyi Biotec, Illumina, Bio-Rad Laboratories, Fluidigm Corporation, NanoString Technologies, Agilent Technologies, Abcam Plc, NuGEN Technologies Inc., LumaCyte, PluriSelect Life Science UG & Co. KG, Sysmex Partec, Bio-Techne Corporation, Promega Corporation, 10x Genomics, WaferGen Bio-systems, Bruker, and Fluxion Bioscience.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org